Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.30 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.30 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189759 | 0.86 | LMNA (0.37) | PDE3BPDE3AMAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL411263 | 0.85 | ALDH1A1 (0.43) | MAPK1 | |
| SCHEMBL10189757 | 0.82 | MAPK1 (0.33) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189779 | 0.82 | MAPK1 (0.34) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189775 | 0.80 | MAPT (0.34) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189782 | 0.80 | ALDH1A1 (0.35) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189764 | 0.79 | KIT (0.37) | PDE3BPDE3A | |
| SCHEMBL10189784 | 0.79 | ALDH1A1 (0.33) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189778 | 0.78 | BRD4 (0.32) | PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL10189766 | 0.76 | CASP3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885PDE3B 1992/4885PDE3A 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.